Best Uterine cancer oncologists in Turkey: TOP 44 doctors

• Dr. Bülent Karagöz specializes in uterine cancer treatment, utilizing surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy.
• Dr. Bülent Karagöz has experience in international practice at medical institutions in Turkey, NATO KFOR Command, and Turkish Cypriot Peace Forces Command.
• With over 20 years of experience in oncology, Dr. Karagöz has conducted extensive research in tumor biology and immunology.
• As a member of the Turkish Medical Oncology Association, Dr. Karagöz adheres to the highest medical standards.
• He is also a professor at Istanbul Okan University Faculty of Medicine, where he contributes to academic and clinical advancements.

• Mustafa Solak, M.D. specializes in uterine cancer treatment using advanced surgical and chemotherapeutic methods.
• Standard treatment options for uterine cancer include surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy.
• International training at the University of Texas MD Anderson Cancer Center, USA.
• Graduated from Hacettepe University School of Medicine; residency at Istanbul Sisli Etfal Teaching and Research Hospital.
• Professional memberships: Fellowship at Hacettepe University Cancer Institute, focusing on oncology.

• Specializes in uterine cancer treatment using surgery, radiation therapy, chemotherapy, and targeted therapy.
• The doctor has experience of international practice at clinics in Turkey, the USA, Israel, and the UK.
• Certified by the European Society of Medical Oncology (ESMO).
• Member of ESMO and European School of Oncology (ESO).
• Languages spoken: English, Russian (B1 level), Turkish.

Dr. Esra Ozbasli is a board-certified OB-GYN and Genital Aesthetics Surgeon. She has over 21 years of experience and is one of Istanbul’s leading specialists. Dr. Ozbasli is known for her skills in minimally invasive gynecologic and genital aesthetic procedures. She performs robotic surgery and cosmetic gynecology with advanced techniques.

She holds certifications in Genital Aesthetics, Cosmetic Gynecology, and da Vinci Robotic Surgery. Dr. Ozbasli is also ECFMG-accredited. She has published many articles in international journals and has trained other specialists. Her work shows a strong commitment to research and education. Dr. Ozbasli speaks English fluently and provides patient-centered care. She uses the latest technology to achieve the best results for her patients.

Assoc. Prof. Gorkem Turkkan started his medical education at Gülhane Military Medical Academy in 2003 and completed it at Zonguldak Karaelmas (Bülent Ecevit) University Faculty of Medicine in 2009. He completed his specialization at Trakya University Faculty of Medicine, Department of Radiation Oncology and became a radiation oncology specialist in 2016.

After completing his compulsory service, he served as a Lecturer and Head of Department at Muğla Sıtkı Koçman University Faculty of Medicine, Department of Radiation Oncology, from May 2019 to February 2021. Meanwhile, between March and June 2020, he worked as a clinical researcher at Maastricht University Faculty of Medicine Department of Radiation Oncology – MAASTRO Clinic (Netherlands) on stereotactic radiotherapy, thoracic radiotherapy-related lung toxicity and proton therapy. While he was working at İstinye University Faculty of Medicine, Department of Radiation Oncology and Liv Hospital Ulus Radiation Oncology Clinic between March 2021 and April 2023, he received the title of Associate Professor in February 2023. She has been serving her patients at Hisar Hospital Intercontinental since May 2023.

He has performed both traditional radiotherapy and advanced radiotherapy throughout his career. He is one of the experienced physicians in our country in stereotactic radiotherapy and MRI-guided radiotherapy treatments, which have become increasingly popular and used especially recently. So far, he has successfully completed more than 2500 radiotherapy sessions with the MR-Linac device.

He has been a member of the Turkish Society of Radiation Oncology (TROD) since 2013 and the European Society of Radiotherapy and Oncology (ESTRO) since 2015. He has 27 articles published in domestic and international journals, 31 oral-poster presentations presented at national and international congresses, and 5 book chapters published by national and international publishing houses. He taught Term I and Term V undergraduate courses at Muğla Sıtkı Koçman University Faculty of Medicine, postgraduate courses within the scope of Ear Nose and Throat Department Specialization training, and Radiotherapy associate degree courses at İstinye University Vocational School of Health Services. She is currently working on 2 ongoing TÜBİTAK Projects. He is married and has a son.

MEDICAL INTERESTS

MR-Linac

Linac

Stereotactic (Pinpoint) Radiotherapy

Prostate Cancers

Breast Cancers

Lung Cancers

Rectum Cancers

Brain and Spinal Cord Cancers

Head and Neck Cancers

Volumetric Arc Therapy (VMAT)

Intensity Modulated Radiotherapy (IMRT)

Prof. Hale Başak Çağlar is a radiation oncology director and expert in treating breast, lung, pancreatic, prostate and bone cancer. She is highly qualified, having obtained her education from Gazi University, Marmara University and Medipol University, and is a member of numerous societies, such as the American Society for Therapeutic Radiation Oncology, the European Society for Therapeutic Radiation Oncology, the European Organisation for Research and Treatment of Cancer and the Radiosurgery Society.

Professor Dr. Mehmet Karaca

DOB: 1971, 

Place Of. Birth: Antalya. 

Foreign Languages ​​Known: English

Medical Interests Cancer Center Schools / trainings Professor of Gynecology and Obstetrics

Medical Interests gynecological cancers Pregnancy high risk pregnancy laparoscopic surgery Urogynecology genital aesthetics in

 Schools / trainings

1993 - Undergraduate Medicine Akdeniz University    

1993 - Master's Degree in Medicine Akdeniz University     1999 - PhD in Obstetrics and Gynecology, Dicle University    

2011 - Minor Gynecological oncology surgery Ministry of Health experiences

2002 - 2005 - Gaziantep University - faculty of medicine - faculty member

2006 - 2010 - Kafkas University faculty of medicine - faculty member

2010 - 2014 - Antalya Training and Research Hospital - clinical chief

2014 - 2021 - Medstar Yıldız Hospital

2018 - 2021 - Gelisim University faculty member

2021 - present - Medical Park Antalya Hospital Complex

Personal Information 

Sex:  Male

Born : 1968 

Professional Experience

Gayrettepe Florence Nigthingale Hospital

Medical Oncology Department

Besiktas/Istanbul/Turkey (ongoing)

Education:

He became Professor (22/April /2016)

Medical Oncology

Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

Istanbul University Oncology Institue,

Department of Medical Oncology

Medical Oncology Fellowship (December 2001-December2004)

Istanbul University, Istanbul Medical Faculty

Hemodialysis Traning (May1996-January1997)

Istanbul University ,bCerrahpasa Medical Faculty

Internal Medicine Residency (November 1991-November 1996)

Istanbul University ,bCerrahpasa Medical Faculty

Ege University Medical Faculty (1985-1991)

Professional Experience

February 1999-November 2001

Metropolitan Florence Nigthingale Hospital

American Cancer Center, Gayrettepe/İstanbul

April1997- October 1998

Bayraktar Dialysis Center

Güngören/ Istanbul

Membership

Turkish Medical Oncology Association

ENET(European Neuroendocrine Tumour Society)

ESMO

ASCO

Education and Career

2011 – 2015, (Internal Medicine Specialist) Istanbul University Istanbul School of Education and Career

Medicine Department of Internal Medicine

2015 – 2016, (Internal Medicine) Specialist Istanbul Haydarpasa Numune Training and Research Hospital

2016 – 2019, (Medical Oncology) Istanbul University Istanbul School of Medicine Department of Medical Oncology

2019 – 2021, (Medical Oncology Specialist) - Istanbul Haydarpasa Numune Training and Research Hospital

2021 – 2024, (Associate Professor) Marmara University School of Medicine Department of Medical Oncology

Memberships in Scientific Organizations

ASCO

ESMO

TTOD 

AVOD 

Publications

In the field of oncology, he has published over 30 peer-reviewed articles at both international and national levels.

Awards Received

EAACI The European Academy of Allergy and Clinical Immunology 2019 Best Poster Award

"The top 3rd verbal presentation, IGICC (11th International Gastrointestinal Cancers Conference – IGICC2021)"

Speeches Delivered at National Congresses, Conferences, and Symposia:

Courses, Meetings, and Certificates

ESMO certified Medical Oncologist since 2019

Dr. Duygu Derin is an experienced medical oncologist who specializes in treating gastrointestinal cancers, lung cancer, and gynecologic neoplasms. She is a member of several oncology associations and has published more than 30 national and international scientific papers. She graduated from Galatasaray Medical High School and achieved a Medical Doctor rank from the Medical Faculty of Istanbul University. She has completed internships and professional development courses in various hospitals and holds the title of Associate Professor.

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

Experience

2021 year - 2022 year

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2021 year - 2022 year

Department of Radiation Oncology, Biruni University Faculty of Medicine

2020 year - 2021 year

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2017 year - 2020 year

Clinical Manager of Radiation Oncology, Neolife Medical Center

2016 year - 2017 year

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2011 year - 2016 year

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2010 year - 2011 year

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2008 year - 2010 year

Radiation Oncology Clinic, Samsun Training and Research Hospital (Education Coordinator)

2006 year

Medical Faculty, Dokuz Eylül University

2006 year - 2008 year

Radiation Oncology Clinic, Samsun Mehmet Aydın State Hospital (Compulsory Service)

2000 year - 2006 year

Medical Faculty, Dokuz Eylül University

Education

2022 year

Biruni University Faculty of Medicine, Department of Radiation Oncology, Faculty Member, Professor Doctor

2022 year

Anadolu University Open Education Faculty Undergraduate Program, Cultural Heritage and Tourism

2021 year

Feyziye Schools Foundation Işık University Health Services Vocational School, Faculty Member, Associate Professor Doctor

2017 year

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Faculty Member

2017 year

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Associate Professor Doctor

2006 year

Samsun Training and Research Hospital, Specialist Doctor, Compulsory Service

2006 year

Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, Medical Specialization

1998 year

Ege University, Faculty of Medicine

Personal information

Title: Professor Doctor

Branch: Radiation Oncology

Work History:

1 GATA Military Medical Faculty

2 Gayrettepe Florence Nightingale Hospital

3 T.R. Demiroğlu Bilim University \ Associate Professor

4 T.R Demiroğlu Bilim University \ Professor

Medical Specialties and Subspecialties:

1 Head and Neck Cancers

2 Radiation Oncology

Priority treatments:

1 Prostate cancer

2 Conformal treatments

Special advanced health technologies:

1 Truebeam Stx Technology

2 Halcyons

Education

1991 - Istanbul University Istanbul Faculty of Medicine

1996 - Istanbul University Cerrahpaşa Faculty of Medicine Radiation

Oncology Specialization Training

Fields of Study and Interests

 Breast Cancer

 Lung Cancer

 Colon Cancer

 Stomach Cancer

 Rectum Cancer

 Ovarian Cancer

 Uterine Cancer

 Liver Cancer

 Esophageal Cancer - Esophagus Cancer

 Kidney Cancer

 Larynx Cancer - Throat Cancer

 Thyroid Cancer

 Head and Neck Cancers

 Gynecological Cancers

 Pancreatic Cancer

 Esophageal Cancer - Esophagus Cancer

 Uterine Cancer

 Brain Cancers - Brain Tumors

 Soft Tissue Cancer - Sarcomas

 Prostate Cancer

 Bladder Cancer

 Bile Duct Cancer

 Testicular Cancer

 Cervical Cancer

 Mouth, Tongue, Lip Cancers

 Gastrointestinal Sy Cancers

 Bone Tumors

 Trachea and Bronchial Cancers

 Skin Cancers - Skin Cancers

 Skeletal Sy Tumors

 Gallbladder Cancer

 Mesothelioma

Education

 Cumhuriyet University Faculty of Medicine, 2004

 Istanbul Haydarpaşa Education and Research Hospital Internal Medicine Specialist, 2010

 Karadeniz Technical University Faculty of Medicine Medical Oncology Specialist, 2015

Career

 MD Andeson Cancer Center, USA, 2008

 Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017

 Moffit Cancer Center, USA 2022

 Istanbul Haydarpaşa Education and Research Hospital Internal Medicine, 2010

 İdil State Hospital Internal Medicine Clinic, 2011

 Karadeniz Technical University Faculty of Medicine Medical Oncology Clinic, 2015

 Istanbul Göztepe Education and Research Hospital Medical Oncology Clinic, 2018

 Yeniyüzyıl University Gaziosmanpaşa Hospital Medical Oncology Clinic, 2020

 Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Education and Expertise

Selcuk University Meram Faculty of Medicine - Medical Education

Dr.Abdurrahman Yurtaslan Anakara Oncology Training and Research Hospital Medical Oncology Specialization

Experience

Malatya State Hospital Internal Diseases Clinic

Ankara Oncology Hospital Medical Oncology Clinic

Erzurum Regional Training and Research Hospital Medical Oncology Clinic


AREAS OF INTEREST

Lung cancer

esophageal cancer

Gastric cancer

breast cancer

Gastrointestinal surgery

https://scholar.google.com.tr/citations?user=EDuylhoAAAAJ&hl=tr 

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Education & Expertise

• 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
• 2005 to 2009 – Düzce University, Internal Medicine Specialization
• 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
• 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
• 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
• 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
• 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
• 2020 to Present – Professor, Sakarya University Faculty of Medicine
• 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

Experience

• 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
• 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

Professional Memberships

• TTOD (Turkish Society of Medical Oncology)
• ASCO (American Society of Clinical Oncology)
• ESMO (European Society for Medical Oncology)

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

Medical Intrests

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Rectal Cancer
• Ovarian Cancer
• Liver Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Kidney Cancer
• Larynx Cancer - Cancer of the Larynx
• Thyroid Cancer
• Head and Neck Cancers
• Gynaecological Cancers
• Pancreatic Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Uterine Cancer
• Brain Cancers - Brain Tumours
• Soft Tissue Cancer - Sarcomas
• Prostate Cancer
• Bladder Cancer
• Bile Tract Cancer
• Testicular Cancer
• Cervical Cancer
• Mouth, Tongue, Lip Cancers
• Gastrointestinal Sy Cancers
• Bone Tumours
• Trachea and Bronchial Cancers
• Skin Cancers - Skin Cancers
• Skeletal Sy Tumours
• Gallbladder Cancer
• Mesothelioma

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Syic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Syic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)